Overview

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Status:
Completed

Trial end date:
2019-09-04

Target enrollment:

Participant gender:

Summary

This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.

Phase:

Phase 3

Details

Lead Sponsor:

Scynexis, Inc.

Treatments:

Ibrexafungerp